Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Rozenbaum

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Maturitas|November 1, 1996
Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacyH Rozenbaum, M Birkhäuser, C De Nooyer, et al.
Plos One|August 6, 2014
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the NetherlandsJelena Stevanović, Marjolein Pompen, Hoa H Le, et al.
Expert Review of Vaccines|March 3, 2012
A review of the literature on the economics of vaccination against TBHong-Anh T Tu, Hoa D Vu, Mark H Rozenbaum, et al.
BMC Public Health|June 14, 2011
Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus modelMark H Rozenbaum, Marie-Josee J Mangen, Carlo Giaquinto, et al.
BMC Medicine|July 12, 2011
Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the worldMaarten J Postma, Mark Jit, Mark H Rozenbaum, et al.
Maturitas|November 1, 1996
Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerabilityH Rozenbaum, M Birkhäuser, C De Nooyer, et al.
BMJ (Clinical Research Ed.)|October 30, 2012
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysisMark H Rozenbaum, Albert Jan van Hoek, Douglas Fleming, et al.
BMC Infectious Diseases|February 1, 2013
An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model"Hong Anh T Tu, Mark H Rozenbaum, Pieter T de Boer, et al.
Vaccine|May 19, 2015
Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysisMark H Rozenbaum, Marie-Josee J Mangen, Susanne M Huijts, et al.
Vaccines|August 28, 2025
A Novel Approach to Estimate the Impact of PCV20 Immunization in Children by Incorporating Indirect Effects to Generate the Number Needed to VaccinateMark H Rozenbaum, Maria J Tort, Blair Capitano, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Maturitas|November 1, 1996
Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacyH Rozenbaum, M Birkhäuser, C De Nooyer, et al.
Plos One|August 6, 2014
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the NetherlandsJelena Stevanović, Marjolein Pompen, Hoa H Le, et al.
Expert Review of Vaccines|March 3, 2012
A review of the literature on the economics of vaccination against TBHong-Anh T Tu, Hoa D Vu, Mark H Rozenbaum, et al.
BMC Public Health|June 14, 2011
Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus modelMark H Rozenbaum, Marie-Josee J Mangen, Carlo Giaquinto, et al.
BMC Medicine|July 12, 2011
Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the worldMaarten J Postma, Mark Jit, Mark H Rozenbaum, et al.
Maturitas|November 1, 1996
Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerabilityH Rozenbaum, M Birkhäuser, C De Nooyer, et al.
BMJ (Clinical Research Ed.)|October 30, 2012
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysisMark H Rozenbaum, Albert Jan van Hoek, Douglas Fleming, et al.
BMC Infectious Diseases|February 1, 2013
An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model"Hong Anh T Tu, Mark H Rozenbaum, Pieter T de Boer, et al.
Vaccine|May 19, 2015
Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysisMark H Rozenbaum, Marie-Josee J Mangen, Susanne M Huijts, et al.
Vaccines|August 28, 2025
A Novel Approach to Estimate the Impact of PCV20 Immunization in Children by Incorporating Indirect Effects to Generate the Number Needed to VaccinateMark H Rozenbaum, Maria J Tort, Blair Capitano, et al.
Pageof 8